Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02829957 · ClinicalTrials.gov registry record · Phase 2
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02829957 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 19 participants.
The verdict
NCT02829957, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.
Interventions
- DRUG Apixaban
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-09 |
| Est. Completion | 2020-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02829957
The ClinicalTrials.gov registry entry for NCT02829957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT02829957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02829957 about?
NCT02829957 is a clinical study titled "RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding". A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.
What is the current status of trial NCT02829957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-09. Estimated completion is 2020-02-13.
What interventions are being tested in trial NCT02829957?
The interventions under investigation include: Apixaban (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT02829957?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.